Participants of the SERES-012 study may decide at Week 8 (if eligible) to join SERES-013, a follow on study in which all participants will receive the study drug.
Patients who are eligible to join the study will take 4 pills daily for 3 days in a row. Visits are by phone and in-person. Side effects and benefits will be noted by questionnaires, symptom diary records and through tests like stool and urine samples, blood draws and physical exam by the study doctor.
What we're hoping for
To show that the study drug SER-109 is safe and helpful in the treatment of recurrent Clostridium difficile Infection
ClinicalTrials.gov Identifier: NCT03183141